Rs6265

Last updated
SNP: rs6265
Name(s)Val66Met, V66M, G196A
Gene BDNF
Chromosome 11
External databases
Ensembl Human SNPView
dbSNP 6265
HapMap 6265
SNPedia 6265
AlzGene Meta-analysis
Overview
SzGene Meta-analysis
Overview
PDGene Meta-analysis
Overview

Rs6265, also called Val66Met or G196A, is a gene variation, a single nucleotide polymorphism (SNP) in the BDNF gene that codes for brain-derived neurotrophic factor.

Contents

Well over a hundred research studies have examined the polymorphism.

Association with neuropsychiatric disorders

A number of studies have examined the role of this polymorphism in risk of neuropsychiatric disorders [1] , including schizophrenia [2] and depression. [3] It is generally thought that some variants of the polymorphism lead to memory impairment and susceptibility to neuropsychiatric disorders, [4] and a 2007 meta-analysis of case-control studies found a relationship between the SNP and substance-related disorders, eating disorders, and schizophrenia. [5] Another 2007 meta-analysis could, however, find no association between the SNP and schizophrenia or bipolar disorder. [6] Meta-analyses of Alzheimer's disease and Parkinson's disease also indicate that the SNP has little or no association with these diseases. [7] [8] Also inconsistencies in association studies with depression have been noted. [9]

The reason for these inconsistent results have been suggested to stem from several sources, with one recent review arguing that statistical artefact, sampling bias, population stratification and uncontrolled gene-environment interactions are likely to underscore this effect [1] . These same authors recently published a report which found that transgenic mice engineered to express human BDNF as well as carry the Val66Met permutation are selectively sensitive to the glucocorticoid stress hormone corticosterone (rodent equivalent of cortisol), which in turn primes the fear circuitry and hippocampus-dependent memory function of Met/Met homozygous mice [10] . As hippocampal function is a core component of several psychiatric conditions, and stress is a non-specific but substantial risk factor for affective, anxiety, eating and psychotic disorders, Notaras et al. argue that "there is a long-term effect of glucocorticoids in 66Met carriers that potentiates the fear circuitry into adulthood, which may increase susceptibility to trauma, events with negative emotional valence and related psychopathology". [10] This interpretation is consistent with a suggested role of BDNF and the Val66Met polymorphism in post-traumatic stress disorder, [1] [11] where it has been shown that 66Met variant perturbs extinction learning in both man and mouse. [12] The Val66Met polymorphism alters vulnerability to stress in mice and humans, which likely contributes to PTSD risk. [13]

In treatment response studies val/val homozygotes may respond better than met allele carriers with drug resistant depression treated with repetitive transcranial magnetic stimulation. [14]

Subject variables in healthy humans

One study has reported that met/met carriers tends to have lower body mass index compared to the two other genotypes. [15] Another study showed that subjects with the val/val genotype had higher mean intelligence. The same study found no association with personality traits as measured with the Tridimensional Personality Questionnaire. [16] Also a Polish 2007 study observed no significant relationship between the polymorphism and personality in healthy females. [17] A German 2005 study could though find an association with personality traits measured with NEO-Five Factor Inventory, with Val/Val subjects scoring higher on anxiety and neuroticism dimensions. [18] Large studies and a meta-analysis inclusive of over 15,000 subjects, however, found no association between the Val66Met and Neuroticism. [19]

Other studies

A study in transgenic mice has found that met/met mice exhibits increased anxiety-related behaviors. [20]

Related Research Articles

<span class="mw-page-title-main">Serotonin transporter</span> Mammalian protein found in humans

The serotonin transporter also known as the sodium-dependent serotonin transporter and solute carrier family 6 member 4 is a protein that in humans is encoded by the SLC6A4 gene. SERT is a type of monoamine transporter protein that transports the neurotransmitter serotonin from the synaptic cleft back to the presynaptic neuron, in a process known as serotonin reuptake.

Schizotypal personality disorder, also known as schizotypal disorder, is a cluster A personality disorder. The Diagnostic and Statistical Manual of Mental Disorders (DSM) classification describes the disorder specifically as a personality disorder characterized by thought disorder, paranoia, a characteristic form of social anxiety, derealization, transient psychosis, and unconventional beliefs. People with this disorder feel pronounced discomfort in forming and maintaining social connections with other people, primarily due to the belief that other people harbor negative thoughts and views about them. Peculiar speech mannerisms and socially unexpected modes of dress are also characteristic. Schizotypal people may react oddly in conversations, not respond, or talk to themselves. They frequently interpret situations as being strange or having unusual meanings for them; paranormal and superstitious beliefs are common. Schizotypal people usually disagree with the suggestion that their thoughts and behaviors are a 'disorder' and seek medical attention for depression or anxiety instead. Schizotypal personality disorder occurs in approximately 3% of the general population and is more commonly diagnosed in males.

<span class="mw-page-title-main">Brain-derived neurotrophic factor</span> Protein

Brain-derived neurotrophic factor (BDNF), or abrineurin, is a protein that, in humans, is encoded by the BDNF gene. BDNF is a member of the neurotrophin family of growth factors, which are related to the canonical nerve growth factor (NGF), a family which also includes NT-3 and NT-4/NT-5. Neurotrophic factors are found in the brain and the periphery. BDNF was first isolated from a pig brain in 1982 by Yves-Alain Barde and Hans Thoenen.

Catechol-<i>O</i>-methyltransferase Class of enzymes

Catechol-O-methyltransferase is one of several enzymes that degrade catecholamines, catecholestrogens, and various drugs and substances having a catechol structure. In humans, catechol-O-methyltransferase protein is encoded by the COMT gene. Two isoforms of COMT are produced: the soluble short form (S-COMT) and the membrane bound long form (MB-COMT). As the regulation of catecholamines is impaired in a number of medical conditions, several pharmaceutical drugs target COMT to alter its activity and therefore the availability of catecholamines. COMT was first discovered by the biochemist Julius Axelrod in 1957.

<span class="mw-page-title-main">Monoamine oxidase A</span> Endogenous enzyme

Monoamine oxidase A, also known as MAO-A, is an enzyme that in humans is encoded by the MAOA gene. This gene is one of two neighboring gene family members that encode mitochondrial enzymes which catalyze the oxidative deamination of amines, such as dopamine, norepinephrine, and serotonin. A mutation of this gene results in Brunner syndrome. This gene has also been associated with a variety of other psychiatric disorders, including antisocial behavior. Alternatively spliced transcript variants encoding multiple isoforms have been observed.

<span class="mw-page-title-main">Tropomyosin receptor kinase B</span> Protein and coding gene in humans

Tropomyosin receptor kinase B (TrkB), also known as tyrosine receptor kinase B, or BDNF/NT-3 growth factors receptor or neurotrophic tyrosine kinase, receptor, type 2 is a protein that in humans is encoded by the NTRK2 gene. TrkB is a receptor for brain-derived neurotrophic factor (BDNF). Standard pronunciation is "track bee".

<span class="mw-page-title-main">Neurotrophin-3</span> Protein-coding gene in the species Homo sapiens

Neurotrophin-3 is a protein that in humans is encoded by the NTF3 gene.

Psychiatric genetics is a subfield of behavioral neurogenetics and behavioral genetics which studies the role of genetics in the development of mental disorders. The basic principle behind psychiatric genetics is that genetic polymorphisms are part of the causation of psychiatric disorders.

The glutamate hypothesis of schizophrenia models the subset of pathologic mechanisms of schizophrenia linked to glutamatergic signaling. The hypothesis was initially based on a set of clinical, neuropathological, and, later, genetic findings pointing at a hypofunction of glutamatergic signaling via NMDA receptors. While thought to be more proximal to the root causes of schizophrenia, it does not negate the dopamine hypothesis, and the two may be ultimately brought together by circuit-based models. The development of the hypothesis allowed for the integration of the GABAergic and oscillatory abnormalities into the converging disease model and made it possible to discover the causes of some disruptions.

rs6295, also called C(-1019)G, is a gene variation—a single nucleotide polymorphism (SNP)—in the HTR1A gene. It is one of the most investigated SNPs of its gene. The C-allele is the most prevalent with 0.675 against the G-allele with 0.325 among Caucasian.

5-HTTLPR is a degenerate repeat polymorphic region in SLC6A4, the gene that codes for the serotonin transporter. Since the polymorphism was identified in the middle of the 1990s, it has been extensively investigated, e.g., in connection with neuropsychiatric disorders. A 2006 scientific article stated that "over 300 behavioral, psychiatric, pharmacogenetic and other medical genetics papers" had analyzed the polymorphism. While often discussed as an example of gene-environment interaction, this contention is contested.

In genetics, rs1800955 is a single nucleotide polymorphism (SNP). It is located in the promoter region of the DRD4 gene. This gene codes for the dopamine receptor D4.

The C957T gene polymorphism is a synonymous mutation located within the 957th base pair of the DRD2 gene. This base pair is located in exon 7. Most synonymous mutations are silent. However, the C957T mutation is an exception to this rule. While the 957C allele codes for the same polypeptide as the 957T allele, the conformation of 957T messenger RNA differs from the conformation of 957C messenger RNA. 957T messenger RNA is less stable and more prone to degradation. Dopamine D2 receptor expression is increased among individuals who carry the 957T allele compared to individuals who carry the 957C allele.

The evolution of schizophrenia refers to the theory of natural selection working in favor of selecting traits that are characteristic of the disorder. Positive symptoms are features that are not present in healthy individuals but appear as a result of the disease process. These include visual and/or auditory hallucinations, delusions, paranoia, and major thought disorders. Negative symptoms refer to features that are normally present but are reduced or absent as a result of the disease process, including social withdrawal, apathy, anhedonia, alogia, and behavioral perseveration. Cognitive symptoms of schizophrenia involve disturbances in executive functions, working memory impairment, and inability to sustain attention.

The epigenetics of schizophrenia is the study of how inherited epigenetic changes are regulated and modified by the environment and external factors and how these changes influence the onset and development of, and vulnerability to, schizophrenia. Epigenetics concerns the heritability of those changes, too. Schizophrenia is a debilitating and often misunderstood disorder that affects up to 1% of the world's population. Although schizophrenia is a heavily studied disorder, it has remained largely impervious to scientific understanding; epigenetics offers a new avenue for research, understanding, and treatment.

Epigenetics of depression is the study of how epigenetics contribute to depression.

<span class="mw-page-title-main">ANA-12</span> Chemical compound

ANA-12 is a selective, small-molecule non-competitive antagonist of TrkB, the main receptor of brain-derived neurotrophic factor (BDNF). The compound crosses the blood-brain-barrier and exerts central TrkB blockade, producing effects as early as 30 minutes and as long as 6 hours following intraperitoneal injection in mice. It blocks the neurotrophic actions of BDNF without compromising neuron survival.

<span class="mw-page-title-main">Biology of bipolar disorder</span> Biological Study Of Bipolar Disorder

Bipolar disorder is an affective disorder characterized by periods of elevated and depressed mood. The cause and mechanism of bipolar disorder is not yet known, and the study of its biological origins is ongoing. Although no single gene causes the disorder, a number of genes are linked to increase risk of the disorder, and various gene environment interactions may play a role in predisposing individuals to developing bipolar disorder. Neuroimaging and postmortem studies have found abnormalities in a variety of brain regions, and most commonly implicated regions include the ventral prefrontal cortex and amygdala. Dysfunction in emotional circuits located in these regions have been hypothesized as a mechanism for bipolar disorder. A number of lines of evidence suggests abnormalities in neurotransmission, intracellular signalling, and cellular functioning as possibly playing a role in bipolar disorder.

Epigenetics of bipolar disorder is the effect that epigenetics has on triggering and maintaining the bipolar disorder.

The neurotrophic hypothesis of depression proposes that major depressive disorder (MDD) is caused, at least partly, by impaired neurotrophic support. Neurotrophic factors are a family of closely related proteins which regulate the survival, development, and function of neurons in both the central and peripheral nervous systems. 

References

  1. 1 2 3 Notaras, M.; Hill, R.; van den Buuse, M. (2015-08-01). "The BDNF gene Val66Met polymorphism as a modifier of psychiatric disorder susceptibility: progress and controversy". Molecular Psychiatry. 20 (8): 916–930. doi: 10.1038/mp.2015.27 . ISSN   1359-4184. PMID   25824305.
  2. ↑ Notaras, Michael; Hill, Rachel; van den Buuse, Maarten (2015-04-01). "A role for the BDNF gene Val66Met polymorphism in schizophrenia? A comprehensive review". Neuroscience & Biobehavioral Reviews. 51: 15–30. doi:10.1016/j.neubiorev.2014.12.016. PMID   25562189. S2CID   25716989.
  3. ↑ Ribeiro L, Busnello JV, Cantor RM, Whelan F, Whittaker P, Deloukas P, Wong ML, Licinio J (August 2007). "The brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism and depression in Mexican-Americans". NeuroReport . 18 (12): 1291–1293. doi:10.1097/WNR.0b013e328273bcb0. PMC   2686836 . PMID   17632285.
  4. ↑ Kevin G. Bath & Francis S. Lee (March 2006). "Variant BDNF (Val66Met) impact on brain structure and function". Cognitive, Affective, & Behavioral Neuroscience . 6 (1): 79–85. doi: 10.3758/CABN.6.1.79 . PMID   16869232.
  5. ↑ Mònica Gratacòs, Juan R. González, Josep M. Mercader, Rafael de Cid, Mikel Urretavizcaya & Xavier Estivill (April 2007). "Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia". Biological Psychiatry . 61 (7): 911–912. doi: 10.1016/j.biopsych.2006.08.025 . PMID   17217930. S2CID   34873602.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ↑ Kanazawa, Tetsufumi; Glatt, Stephen J.; Kia-Keating, Brett; Yoneda, Hiroshi; Tsuang, Ming T (June 2007). "Meta-analysis reveals no association of the Val66Met polymorphism of brain-derived neurotrophic factor with either schizophrenia or bipolar disorder". Psychiatric Genetics . 17 (3): 165–170. doi:10.1097/YPG.0b013e32801da2e2. PMID   17417060. S2CID   25579523.
  7. ↑ "META-ANALYSIS OF ALL PUBLISHED AD ASSOCIATION STUDIES (CASE-CONTROL ONLY) rs6265". Alzheimer Research Forum. Archived from the original on 2013-02-23. Retrieved 2008-06-20.
  8. ↑ E. Zintzaras E; G. M. Hadjigeorgiou (2005). "The role of G196A polymorphism in the brain-derived neurotrophic factor gene in the cause of Parkinson's disease: a meta-analysis". J. Hum. Genet. 50 (11): 560–566. doi: 10.1007/s10038-005-0295-z . PMID   16172806.
  9. ↑ J. O. Groves (December 2007). "Is it time to reassess the BDNF hypothesis of depression?". Molecular Psychiatry . 12 (12): 1079–88. doi: 10.1038/sj.mp.4002075 . PMID   17700574.
  10. 1 2 Notaras, M.; Hill, R.; Gogos, J. A.; van den Buuse, M. (2015-10-06). "BDNF Val66Met genotype determines hippocampus-dependent behavior via sensitivity to glucocorticoid signaling". Molecular Psychiatry. 21 (6): 730–2. doi:10.1038/mp.2015.152. ISSN   1476-5578. PMC   4879187 . PMID   26821977.
  11. ↑ Zhang, L.; Benedek, D. M.; Fullerton, C. S.; Forsten, R. D.; Naifeh, J. A.; Li, X. X.; Hu, X. Z.; Li, H.; Jia, M. (2014-01-01). "PTSD risk is associated with BDNF Val66Met and BDNF overexpression". Molecular Psychiatry. 19 (1): 8–10. doi: 10.1038/mp.2012.180 . ISSN   1359-4184. PMID   23319005.
  12. ↑ Soliman, Fatima; Glatt, Charles E.; Bath, Kevin G.; Levita, Liat; Jones, Rebecca M.; Pattwell, Siobhan S.; Jing, Deqiang; Tottenham, Nim; Amso, Dima (2010-02-12). "A Genetic Variant BDNF Polymorphism Alters Extinction Learning in Both Mouse and Human". Science. 327 (5967): 863–866. Bibcode:2010Sci...327..863S. doi:10.1126/science.1181886. ISSN   0036-8075. PMC   2829261 . PMID   20075215.
  13. ↑ Notaras, Michael; van den Buuse, Maarten (2020-01-03). "Neurobiology of BDNF in fear memory, sensitivity to stress, and stress-related disorders". Molecular Psychiatry. 25 (10): 2251–2274. doi:10.1038/s41380-019-0639-2. ISSN   1476-5578. PMID   31900428. S2CID   209540967.
  14. ↑ Luisella Bocchio-Chiavetto, Carlo Miniussi, Roberta Zanardini, Anna Gazzoli, Stefano Bignotti, Claudia Specchia & Massimo Gennarelli (May 2008). "5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression" (PDF). Neuroscience Letters . 437 (2): 130–134. doi:10.1016/j.neulet.2008.04.005. hdl: 11572/145667 . PMID   18450378. S2CID   36187651.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  15. ↑ John Gunstad; Peter Schofield; Robert H. Paul; Mary Beth Spitznagel; Ronald A. Cohen; Leanne M. Williams; Michael Kohn; Evian Gordon (2006). "BDNF Val66Met Polymorphism Is Associated with Body Mass Index in Healthy Adults". Neuropsychobiology . 53 (3): 153–156. doi:10.1159/000093341. PMID   16707914. S2CID   45218374.
  16. ↑ Shih-Jen Tsaia; Chen-Jee Hong; Younger W.-Y. Yuc; Tai-Jui Chen (2004). "Association Study of a Brain-Derived Neurotrophic Factor (BDNF) Val66Met Polymorphism and Personality Trait and Intelligence in Healthy Young Females". Biological Psychiatry . 49 (1): 13–16. doi:10.1159/000075333. PMID   14730195. S2CID   45591436.
  17. ↑ Rybakowski F, Dmitrzak-Weglarz M, Szczepankiewicz A, Skibinska M, Slopien A, Rajewski A, Hauser J (April 2007). "Brain derived neurotrophic factor gene Val66Met and -270C/T polymorphisms and personality traits predisposing to anorexia nervosa". Neuro Endocrinol. Lett. 28 (2): 153–158. PMID   17435670.
  18. ↑ Undine E. Lang; Rainer Hellweg; Peter Kalus; Malek Bajbouj; Kirsten P. Lenzen; Thomas Sander; Dieter Kunz; Jürgen Gallinat (June 2005). "Association of a functional BDNF polymorphism and anxiety-related personality traits". Psychopharmacology. 180 (1): 95–99. doi:10.1007/s00213-004-2137-7. PMID   15918078. S2CID   32939759.
  19. ↑ Terracciano, Antonio; Tanaka, T.; Sutin, A.R.; Deiana, B.; Balaci, L.; Sanna, S.; Olla, N.; Maschio, A.; Uda, M.; Ferrucci, L.; Schlessinger, D.; Costa, P.T. Jr (2010). "BDNF Val66Met is associated with introversion and interacts with 5-HTTLPR to influence neuroticism". Neuropsychopharmacology. 35 (5): 1083–1089. doi:10.1038/npp.2009.213. PMC   2840212 . PMID   20042999.
  20. ↑ Zhe-Yu Chen; Deqiang Jing; Kevin G. Bath; Alessandro Ieraci; Tanvir Khan; Chia-Jen Siao; Daniel G. Herrera; Miklos Toth; Chingwen Yang; Bruce S. McEwen; Barbara L. Hempstead & Francis S. Lee (October 2006). "Genetic Variant BDNF (Val66Met) Polymorphism Alters Anxiety-Related Behavior". Science . 314 (5796): 140–143. Bibcode:2006Sci...314..140C. doi:10.1126/science.1129663. PMC   1880880 . PMID   17023662.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.